According to the International Forum for the Study of Itch (IFSI), chronic pruritus can be classified into three categories. The etiological classification of pruritus on primarily non-lesional (IFSI II) skin can be challenging, particularly as many patients with internal medicine conditions suffer from accompanying pruritic symptoms. Practical guidance for a structured approach and a current overview of pathophysiological insights as well as topical and systemic therapeutic options are provided by the recently updated European guideline by interdisciplinary pruritus experts, which contains numerous evidence-based recommendations.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
- Bezafibrate
- biliary tract diseases
- Bylvay
- chronic pruritus
- Difelikefalin
- European guideline
- evidence-based recommendations
- gabapentin
- IFSI
- IFSI II
- internal medicine conditions
- International Forum for the Study of Itch
- Kidneys
- Liver
- Montelukast
- Nalbuphin
- Naltrexone
- Odevixibat
- pruritus experts
- pruritus on primarily non-lesional
- Sertraline
You May Also Like
- Esophageal Cancer
A Comparison of Endoscopic and Surgical Innovations
- PMR and LVV: Current EULAR Recommendations
Polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D
SGLT2i, metformin, or both?
- Biophilic Design of Work Environments
Effects on Health, Well-Being, and Productivity
- From symptom to diagnosis
Intrapelvic mass with an ambiguous differential diagnosis
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack